Verified July 2026 · Cited to primary sources

PEG-MGF (Pegylated Mechano Growth Factor): Evidence Grade D. Animal studies only, unproven in humans.

Grade DResearch-onlySafety: amber

The honest verdict

Skip it. PEG-MGF is a chemically reasonable attempt to fix MGF's short half-life, but fixing the delivery of a compound with no proven human effect does not create a proven human effect. Animal data only, banned in sport, unverified injectable. Not worth the risk.

PEG-MGF (Pegylated Mechano Growth Factor) at a glance

Class
PEGylated IGF-1 splice variant peptide
Mechanism
PEG-MGF is the MGF (IGF-1Ec E-domain) peptide conjugated to polyethylene glycol. Native MGF has a very short systemic half-life (minutes); PEGylation slows clearance and is meant to give the peptide time to reach tissue and act on satellite cells. The proposed downstream biology is identical to MGF: satellite cell activation, proliferation, and fusion to support fiber repair and hypertrophy. Whether extending the half-life of a peptide that may not be active in the first place produces a real anabolic effect is exactly the open question.
Also known as
pegylated mechano growth factor, PEG MGF, pegylated MGF
Research applications
  • Muscle injury and regeneration models
  • Satellite cell activation studies
  • Sarcopenia and aged-muscle research
Forms
Lyophilized powder for reconstitution (research chemical)
Legal status
Research-only
WADA (anti-doping)
Prohibited at all times (WADA S2, peptide hormones / growth factors class)
Evidence grade
Grade DAnimal studies only, unproven in humans

How we grade evidence

Every grade comes from a fixed A to F rubric: human-trial strength, not hype or affiliate status. Last verified July 6, 2026.

What is PEG-MGF (Pegylated Mechano Growth Factor)?

MGF with a polyethylene glycol tail bolted on to make it last longer in the blood. Longer half-life, same problem: the evidence is animal-only and no human trial has shown it does anything.

PEG-MGF is the MGF (IGF-1Ec E-domain) peptide conjugated to polyethylene glycol. Native MGF has a very short systemic half-life (minutes); PEGylation slows clearance and is meant to give the peptide time to reach tissue and act on satellite cells. The proposed downstream biology is identical to MGF: satellite cell activation, proliferation, and fusion to support fiber repair and hypertrophy. Whether extending the half-life of a peptide that may not be active in the first place produces a real anabolic effect is exactly the open question.

How strong is the evidence for PEG-MGF (Pegylated Mechano Growth Factor)?

Evidence is animal and in-vitro only. Rodent muscle-injury models report increased satellite cell number and cross-sectional area with PEG-MGF, and the PEGylation rationale (extended half-life) is chemically sound. But there are no controlled human trials, and the parent peptide MGF failed to show activity in a rigorous cell study. Grade D reflects preclinical-only evidence with no human efficacy data.

Primary sources (2)

  1. Fornaro M, et al. MGF peptide has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab, 2014 (PMID 24253050).
  2. Zablocka B, et al. Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? Front Endocrinol, 2012.

What is PEG-MGF (Pegylated Mechano Growth Factor) used for?

PEG-MGF (Pegylated Mechano Growth Factor) is marketed for the goals below. See how it ranks against other peptides in each, by evidence, not hype.

What does PEG-MGF (Pegylated Mechano Growth Factor) cost, and how do you access it legally?

Typical cost

$30 to $70 per 2 mg vial (grey-market research supply)

Marketed as the upgraded, longer-lasting MGF, which is used to justify a higher price. You are still buying preclinical-only biology, and vendor-labeled MGF products are commonly underdosed or mislabeled.

No legal supervised access route right now.

PEG-MGF (Pegylated Mechano Growth Factor) has no compliant US route today. Vials sold "for research use only" are a gray-market fig-leaf, not a legal loophole, so we don't link them. If you pursue PEG-MGF (Pegylated Mechano Growth Factor), do it with a licensed clinician, and re-check its legal status first.

Is PEG-MGF (Pegylated Mechano Growth Factor)safe? Side effects & risks

Limited human safety data, no major documented harms

Injectable research chemical with no approved indication and no controlled human safety data. Growth-factor activity, if real, raises the usual theoretical proliferation concerns. PEGylation adds its own uncertainty since the metabolic fate of the PEG carrier in this specific unapproved product is not characterized. Grey-market purity is unverified. Banned in all sport.

Medical disclaimer: This page is independent editorial information, not medical advice, and Best Peptide For That is not a medical provider. We do not provide dosing. Talk to a licensed clinician before starting, stopping, or changing any peptide or medication. Full medical disclaimer.

FAQ

PEG-MGF (Pegylated Mechano Growth Factor) FAQ

Is PEG-MGF better than regular MGF?

It lasts longer in the bloodstream because of the PEG tail, so in theory it has more time to act. But there is no human evidence that either form builds muscle, so a longer half-life of an unproven effect is not a meaningful upgrade.

Will PEG-MGF help me recover from workouts?

The recovery story is based on rodent muscle-injury studies, not human trials. No controlled human study has shown PEG-MGF improves recovery or hypertrophy.

Is PEG-MGF a legal supplement?

No. It is a research chemical, not an approved or compoundable drug, and it is prohibited at all times under the WADA code.

From our portfolio

Tracking PEG-MGF (Pegylated Mechano Growth Factor)?

Titrate is an iOS app for logging doses, schedules and progress over time, with a reconstitution calculator built in. It tracks, it does not prescribe.

Get Titrate for iOS →

Keep reading

The monthly peptide evidence brief.

What the research and the FDA actually say, in one short email a month. Unsubscribe anytime.

No spam. We never sell your email. Editorial policy.